Subscribe To
‘not just bitcoin price’ — dan tapiero shares tips on navigating the bear market
Dan Tapiero explained that the bear phase is finished and predicted that the space will see new highs i...
June 1, 2023, 10:14 am
Chitogenx highlights milestones achieved in fiscal year
ChitogenX Inc has reported its financial results for the fourth quarter and fiscal year ended January 31, 2023, highlighting some milestones achiev...
June 1, 2023, 8:46 am
Usdjpy daily analysis – june 1, 2023
The USDJPY currency pair has entered a consolidation phase following its previous uptrend from 133.49. ...
June 1, 2023, 2:56 am
Gbpusd daily analysis – june 1, 2023
The GBPUSD currency pair has been trading in a sideways manner, moving within a range bound by the support level at 1.2307 and the resistance level at...
June 1, 2023, 2:43 am
Zylö receives $294,000 nih phase i grant to advance its cutaneous lupus program
Funds to be used to demonstrate efficacy in a new mouse model of cutaneous lupus GREENVILLE, SC, May 31, 2023 (GLOBE NEWSWIRE) — Zylö Therapeutics ...
May 31, 2023, 5:00 pm
Peak pharmaceuticals & retrieve medical announce signed contract with regional medical center
BEDMINSTER, N.J., May 31, 2023 (GLOBE NEWSWIRE) — Peak Pharmaceuticals, Inc. (OTC Pink: PKPH), today announced that its wholly owned subsidiary, Ret...
May 31, 2023, 3:30 pm
Sanofi (sny) nextgen multiple sclerosis drug meets phase ii goal
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the p...
May 31, 2023, 1:16 pm
Tg therapeutics announces data from the ultimate i & ii phase 3 trials of briumvi® (ublituximab-xiiy) in multiple sclerosis to be presented at the 2023 consortium of multiple sclerosis centers annual
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highli...
May 31, 2023, 11:30 am
Intellia therapeutics to present updated interim data from ongoing phase 1/2 study of ntla-2002 for the treatment of hereditary angioedema (hae) at the eaaci hybrid congress 2023
Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the ...
May 31, 2023, 11:30 am
Enphase (enph) extends distribution deal with natec in europe
Enphase (ENPH) extends its distribution deal with Natec, which enables the company to expand its presen...
May 31, 2023, 10:45 am
Pyxis (pyxs) up on advancing cancer therapy candidates
Pyxis' (PYXS) shares rise as the company advances its phase I candidates, PYX-106 and PYX-201, for chal...
May 31, 2023, 10:45 am
Saxony may cpi +6.5% vs +7.6% y/y prior
Given the readings from the state releases so far today, we should likely see the national reading later come in below the estimate of 6.5%. I reckon ...
May 31, 2023, 9:03 am
Bybit joins binance and others to exit from canada
Bybit has become the latest cryptocurrency exchange to announce its exit from the Canadian market due to the country's recent regulatory requirements ...
May 31, 2023, 6:15 am
North rhine westphalia may cpi +5.7% vs +6.8% y/y prior
The drop in annual inflation owes much to a further adjustment in base effects, as the high energy prices from last year are being phased out. But for...
May 31, 2023, 5:36 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am